— AstraZeneca Plc (NYSE: AZN) reported its third-quarter 2019 earnings of $0.23 per share and core earnings of $0.99 per share. This is compared to $0.45 per share expected.
— Total revenue increased by 20% to $6.41 billion versus $6.18 billion expected. This is driven by a 16% jump in product sales.
— Oncology sales jumped by 46% and respiratory sales grew by 15%. Biopharmaceuticals sales increased by 12% and new CVRM sales rose by 8% while sales in other medicines fell by 9%.
— Looking ahead into the full year 2019, the company reiterates its core earnings guidance in the range of $3.50 to $3.70 per share.
— The core operating profit for fiscal 2019 is predicted to increase ahead of product sales.
— For the full year, capital expenditure is anticipated to be broadly stable and restructuring expenses are targeted to reduce versus the prior-year.
Aramark Holdings Corp (NYSE: ARMK) shares closed at about $38.77 on Monday, marking a modest…
S&P Global (NYSE: SPGI), a leading provider of financial intelligence solutions, reported strong earnings growth…
Fiserv Inc. (NASDAQ: FISV) reported its fourth quarter 2025 earnings results today. Revenue increased 1%…
Incyte achieved total revenue of $5.14 billion for the full year 2025, a 21% year-over-year…
CVS Health Corporation (NYSE: CVS) reported record full-year 2025 consolidated revenues of $402.1 billion, a…
Healthcare solutions company CVS Health Corporation (NYSE: CVS) on Monday reported an increase in revenues…